Comparing treatment timing for stage II-IIIB lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is for people with a certain type of lung cancer (non-small cell lung cancer) that can be surgically removed. It tests whether it is better to receive treatment before or after surgery to remove the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that is stage IIA to IIIB and can be surgically removed.
- You are 18 years or older.
- You are in fairly good health (able to do daily activities with some help).
- You have not had chemotherapy or other systemic treatment for lung cancer in the last 5 years, unless it was for early-stage cancer that was cured.
- You have not had treatment for another cancer in the last 3 years (with some exceptions for very early-stage or low-risk cancers).
- You do not have active autoimmune disease, interstitial lung disease, or a history of transplant that would make immune therapy unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase II trial tests whether a penpulimab-based combination treatment, given before and after surgery, can improve outcomes for people with operable, locally advanced non-small cell lung cancer. It mainly aims to treat the cancer earlier (before surgery) and help prevent it from coming back (after surgery).
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
This trial tests if receiving immunotherapy before surgery works better than getting it after surgery for people with stage II to IIIB non-small cell lung cancer. The goal is to see which timing helps prevent the cancer from coming back.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial looks at how lung tumors respond after chemotherapy given before surgery in people with stage IIIA non-small cell lung cancer (NSCLC). It may help doctors understand which past treatments lead to better results, since it uses medical records from approved clinical cases.
Hear when a new Resectable Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.